IP Library Granted Patent US 12673113
Granted Patent B2
US 12673113 · App. 17/596,106 · Granted Jul 7, 2026

Methods and compositions for treating cancer with cancer-targeted adjuvants

Inventors: Jeffrey A. Hubbell (Chicago, IL); David S. Wilson (Chicago, IL); Tiffany M. Marchell (Chicago, IL); Laura T. Gray (Chicago, IL)
Assignee: THE UNIVERSITY OF CHICAGO
A61K47/6883A61K39/3955A61K47/643A61K47/6803A61K47/6851A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673113
App. No.
17/596,106
Granted
Jul 7, 2026
Kind
B2
Abstract

Here, the inventors describe methods and compositions for targeting a TLR agonist to the tumor cell or stroma. Aspects of the disclosure relate to a polypeptide comprising a tumor targeting agent operatively linked to p(Man-TLR). Also disclosed are compositions and methods for treating cancer in a subject comprising administration of the polypeptide comprising the tumor targeting agent linked to p(Man-TLR) to the subject.

Claims (12)

1 . A method for treating cancer, for targeting a TLR agonist to a tumor in a subject, or for increasing the accumulation of a TLR agonist in a tumor in a subject, the method comprising administering a polypeptide comprising a collagen binding domain covalently linked to p(Man-TLR7), wherein the collagen binding domain comprises:

the amino acid sequence of one of SEQ ID NOS: 1, 2, or 8.

2 . The method of claim 1 , wherein the subject has cancer.

3 . The method of claim 1 , wherein the cancer comprises melanoma, lymphoma, bladder, breast, mammary carcinoma, or colon cancer.

4 . The method of claim 3 , wherein the cancer comprises melanoma, breast cancer, or a mammary carcinoma.

5 . The method of claim 1 , wherein the polypeptide or composition is administered systemically, by intravenous injection, intratumorally, or peritumorally.

6 . The method of claim 1 , wherein the polypeptide is further covalently linked to an albumin molecule, wherein the albumin molecule comprises an amino acid sequence having at least 95% sequence identity to one of SEQ ID NOs: 11-14.

7 . The method of claim 1 , wherein the molar ratio of the tumor targeting agent to p(Man-TLR) is 1:5.

8 . The method of claim 1 , wherein the polypeptide is further covalently linked to an albumin molecule, wherein the albumin molecule comprises the amino acid sequence of one of SEQ ID NOs: 11-14.

9 . The method of claim 1 , wherein the cancer comprises a solid tumor.

10 . A method for treating melanoma in a subject, the method comprising administering a polypeptide comprising a collagen binding domain covalently linked to p(Man-TLR7), wherein the collagen binding domain comprises the amino acid sequence of one of SEQ ID NOS: 1, 2, or 8.

11 . The method of claim 10 , wherein the polypeptide is further covalently linked to an albumin molecule and wherein the albumin molecule comprises the amino acid sequence of one of SEQ ID NOs: 11-14.